JPMorgan
SMTC Corp. (Nasdaq: SMTX) 55% HIGHER; reports Q4 EPS of $0.14, versus ($0.01) reported for the same period a year ago. Revenue for the quarter was $51.24 million, compared to $55.26 million in Q408.Z
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) 13% HIGHER; today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).
Zanett Inc. (NASDAQ: ZANE) 11% HIGHER;Possible short squeeze after rising from $0.31 on March 3 to over ...
StreetInsider.com Pre-Open Movers:
Innophos (Nasdaq: IPHS) 25% HIGHER; reports Q1 EPS of $0.43, 20 cents better than the analyst estimate of $0.23. Revenues for the quarter were $162.5 million, versus the consensus of $161.38 million.
Powerwave Technologies (Nasdaq: PWAV) 19% HIGHER; reports Q1 EPS of $0.01, 4 cents better than the analyst estimate of ($0.03). Revenues for the quarter were $226.3 million, versus the consensus of $203.41 million.
Idearc Inc. (NYSE: IAR) 18% HIGHER; reports Q1 EPS of $0.79, 16 cents better than the analyst estimate of $0.63. Revenues for the quarter were $770 million, versus the consensus of $775.65 million.
DivX (Nasdaq: DIVX) 17% HIGHER; reports Q1 EPS of $0.18, 4 cents better than the analyst estimate of $0.14. Revenues for the quarter were $25 million, versus the consensus of $25.04 million. Sees FY08 EPS of $0.52-$0.58, versus the consensus of $0.47.
Obagi Medical Products (Nasdaq: OMPI) 14.8% LOWER ...
StreetInsider.com After-Hours Movers:
DivX (Nasdaq: DIVX) 16% HIGHER; reports Q1 EPS of $0.18, 4 cents better than the analyst estimate of $0.14. Revenues for the quarter were $25 million, versus the consensus of $25.04 million. Sees FY08 EPS of $0.52-$0.58, versus the consensus of $0.47.
Powerwave Technologies (Nasdaq: PWAV) 16% HIGHER; reports Q1 EPS of $0.01, 4 cents better than the analyst estimate of ($0.03). Revenues for the quarter were $226.3 million, versus the consensus of $203.41 million.
Obagi Medical Products (Nasdaq: OMPI) 14.8% LOWER; reports Q1 EPS of $0.13, 5 cents below the analyst estimate of $0.18. Revenues for the quarter were $25.4 million, versus the consensus of $27.14 million. Sees Q2 revenues $27-$28 million versus $29.9 million. Sees Q2 eps 18-20 cents versus 24 cents. Sees ...
